Generic Name:
Pembrolizumab
Project Status:
Complete
Therapeutic Area:
head and neck squamous cell carcinoma (HNSCC)
Manufacturer:
Merck Canada
Brand Name:
Keytruda
Project Line:
Reimbursement Review
Project Number:
PC0216-000
NOC Date:
Details
Strength:
25 mg/mL
Tumour Type:
Head and Neck
Indications:
Head and Neck Squamous Cell Carcinoma (HNSCC)
Funding Request:
First-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) as monotherapy, in adult patients whose tumours have PD-L1 expression [Combined Positive Score (CPS) ≥ 1] as determined by a validated test.
First-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in combination with platinum and fluorouracil (FU) chemotherapy, in adult patients.
Review Status:
Complete
Pre Noc Submission:
Yes
Sponsor:
Merck Canada
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued: